1

Forimmediaterelease PressRelease

MaaTPharmaToReleaseFirstinPatientsDataAtThe2017ASHMeetingOnAutologousFecalMicrobiotaTransferAndRestorationOfMicrobiotaDiversityTheFrenchMicrobiomecompanycompleteditsfirstclinicalstudyprovingthatAutologousFecalMicrobiotaTransferinduceda90%recoveryofgutmicrobiomediversity.Thesepromisingresults

couldopennewavenuesfortreatingseveralconditionsinthehematology-oncologyfield.(Lyon-France) - November 30, 2017 -MaaT Pharma, a French-basedmicrobiome company developinginnovativetreatmentsforunmetmedicalneedsinhematology-oncology,infectiondiseasesandimmunediseases such as GvHD, announces that data related to MaaT011* will be the subject of one posterpresentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exhibition onDecember9-12inAtlanta,USA.*Product:EnemaadministrationofMaaT011,AutologousFecalMicrobiotasuspension,targetingdiversityrestorationfollowingiatrogenicdysbiosis.Thepresentationdetailsareasfollows:

• Abstract Title: Prevention of Dysbiosis Complications with Autologous Fecal MicrobiotaTransplantation (auto-FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing IntensiveTreatment(ODYSSEEstudy):FirstResultsofaProspectiveMulticenterTrial

• Date:Sunday,December10,2017,6:00PM-8:00PM• Location:BldgA,Lvl1,HallA2(GeorgiaWorldCongressCenter)• Session:616.AcuteMyeloidLeukemia:NovelTherapy,excludingTransplantation:PosterII• Presentedby:DrFlorentMalard1&DrEmiliePlantamura2• Abstract:#2624• Link:https://ash.confex.com/ash/2017/webprogram/Paper102744.html

ThispresentationunderlinesthemedicalrationaleoftheuseofFMTinhematology-oncology. ThedesignoftheongoingPhaseI/IIstudy,inAcuteMyeloidLeukemiawillalsobeexplained.“Ourmetagenomicdatashowahugeimpactofinductionchemotherapyandantibioticsonmicrobiomewithdramaticreductionofdiversityatgenusandspecieslevelsandsignificantincreaseoftheantibioticresistancegenecopy-count.”underlinesHervéAffagard,MaaTPharmaCEO. Auto-FMTinducedarecoveryofmicrobiotadiversityashighas90%atthegenuslevelandareturntothebaselineof the resistancegenecopy-count.Asafety reviewbyanexternalDataSafetyMonitoringBoard(DSMB)recentlyconfirmedthesafetyprofileoftheproductinthisveryfragilepatientpopulation.“Themicrobiotacomprehensionentersanamazingandexcitingneweraofknowledge.Ourcapabilitiesindeveloping FMT-based product could open enormous potentialities to treat unmet medical needs.PresentationoftheseresultsatASHannualmeetingsupportstheProofOfConceptofthefirststageofMaaTPharma’sdevelopmentstrategytotreatdysbiosis-relateddiseaseswithanFMT-basedproduct.”saidDavidSalako,TherapeuticDevelopmentDirectoratMaaTPharma.Patients’profilesarecurrentlybeingreviewedtoassessclinicaloutcomes.

1Hematologist,SaintAntoinehospital,Paris,France2Pharm.DandPhD,ClinicalProjectLeader,MaaTPharma,Lyon,France

2

Forimmediaterelease PressRelease

Microbiomeresearch,anInvestmentfortheFutureRecentfindingsinmicrobiomeresearcharepromisingandopennewtherapeuticpathwaysforphysiciansandpatients in infectiousdiseases,cancer, immuno-deficientdiseases,obesity,autism,etc.Meanwhile,scientificpublicationsandinvestmentsinbiotechcompaniesspecializedinthemicrobiomehavemultiplied.Forexample,theUnitedStateshaschosentolaunchin2016"TheNationalMicrobiomeInitiative"withafundofmorethan$120millionforresearch.FrancealsosupportsbiotechcompanieslikeMaaTPharmainthis field, through its PIA investment program.MaaT Pharma is the first MicrobioTech to use GMPCompliantFecalMicrobiotaTransfers(FMT)inpatients.Following its Proof of Concept using MaaT011, MaaT Pharma currently develops drug products usingautologous and allogeneic microbiota transfers. Driven by its exponential growth, MaaT Pharma hasteamedupwithBiocodextodevelopanoralformofitsdrug.AstepfurthertowardsindustrializationofFMTforthisMicrobioTechcompany,whichhasdevelopedthefirstCEmarkeddeviceforstoolcollectionanddilution.

###AboutMaaTPharmaFoundedattheendof2014,MaaTPharma(MicrobiotaasaTherapy),amicrobiome–basedbiopharmaceuticalcompany,revolutionizingandshapingaselectiveapproachtotherapiesinordertotreatdebilitatingdiseaseslinkedtogutmicrobiotaimbalances.Thankstothe€16millioninfundingMaaTPharmaiscurrentlydevelopingarangeofFMTproductsforpatientssufferingfromhematology-oncology,infectiondiseasesandimmunediseasessuchasGvHDtooptimizethesuccessoftheharshmedical treatment associated.MaaT Pharma’s revolutionary and rapid approach plays a considerable part in theevolutionoftailoredtreatmenttherapies.Thankstoastrongscientificandmedicalnetwork,thecompanyisincreasingitspartnershipswithrenownedinstitutionssuchas INRA, and Bioaster and is part of a consortium coordinated by Institut Gustave Roussy to improve the efficacy ofimmunotherapies.Inthecomingmonths,MaaTPharmawillsignificantlypursueitsdevelopmentprogramsinhematologicalandinfectiousindicationsandispreparingitsnextfundraisingwiththeobjectiveoflaunchinganoralformulationoftheFMTdrugproductby2018.MaaT Pharma is backed by its investors who are experts in the Microbiome field and in technological developments:Seventure,CM-CICInnovations,BiocodexandINRA.Foradditionalinformation,pleasevisitwww.maatpharma.comorfollowusonTwitter@MaaT_Pharma.MediaContactPaulineRichaudTBWA\CORPORATEEmail:pauline.richaud@tbwa-corporate.comPhone:0033645684272